US4036977A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polycyclophenylpyrrolidines, their compositions and use
Assignee: Pharmacia and Upjohn Co
•
Filing: 1975-05-12
•
Granted: 1977-07-19
•
Expires: 1995-05-12
Abstract
Abstract Compounds of the formula <IMAGE> where R4X is a polycyclocoupled group and R1 and R2 are H or simple hydrocarbon and R3 has the same value and additionally simple acyl, can be made by a variety of syntheses. They have hypolipedemic and antiatherosclerotic properties, and are useful in that field.
Inventors
- 👤 Daniel Lednicer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 03:55
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/16; C07D295/18; C07D295/182; C07D295/192; C07C; C07C65/00; C07C65/21; C07C65/24; C07C65/26; C07D295/04; C07D295/08; C07D295/096; C07D295/12; C07D295/125; C07D295/13; C07D295/135
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
62 words
A compound of the formula ##STR13## wherein X is O, S, CH 2 , N-lower alkyl or N-lower alkyl carboxyacyl, each alkyl of one to six carbon atoms, inclusive; R 3 is hydrogen, halogen, methyl, 2,6-dimethyl, 3,5-dimethyl, -CHO, -CH 2 OH, -CH(CH 3 )OH, -CH 2 SCH 3 , or pyrrolidino; R 4 is ##STR14## and pharmaceutically acceptable acid addition salts thereof.
Claim 2
Dependent Claim
62 words
A compound of the formula ##STR13## wherein X is O, S, CH 2 , N-lower alkyl or N-lower alkyl carboxyacyl, each alkyl of one to six carbon atoms, inclusive; R 3 is hydrogen, halogen, methyl, 2,6-dimethyl, 3,5-dimethyl, -CHO, -CH 2 OH, -CH(CH 3 )OH, -CH 2 SCH 3 , or pyrrolidino; R 4 is ##STR14## and pharmaceutically acceptable acid addition salts thereof.
Claim 3
Dependent Claim
10 words
A compound of claim 1 wherein R 4 is ##STR15##
Claim 4
Dependent Claim
10 words
A compound of claim 1 wherein R 4 is ##STR16##
Claim 5
Dependent Claim
10 words
A compound of claim 1 wherein R.sub. 4 is ##STR17##
Claim 6
Dependent Claim
10 words
A compound of claim 1 wherein R 4 is ##STR18##
Claim 7
Dependent Claim
10 words
A compound of claim 1 wherein R 4 is ##STR19##
Claim 8
Dependent Claim
10 words
A compound of claim 1 wherein R 4 is ##STR20##
Claim 9
Dependent Claim
7 words
The compound according to claim 1, N,(p-[1-adamantyloxy]phenyl)pyrrolidine.
Claim 10
Dependent Claim
7 words
The compound according to claim 1, 1-(α-1-adamantyl-p-tolyl)pyrrolidine.
Claim 11
Dependent Claim
7 words
The compound according to claim 1, 1-(p-1-adamantylthiophenyl)pyrrolidine.
Claim 12
Dependent Claim
7 words
The compound according to claim 1, N-(p-[2,2,2-bicyclooctyloxy)phenyl)pyrrolidine.
Claim 13
Dependent Claim
7 words
The compound according to claim 1, N-[4-(1-adamantyloxy)-3-chlorophenyl]pyrrolidine.
Claim 14
Dependent Claim
7 words
The compound according to claim 1, N-[4-(1-adamantyloxy)-3,5-dimethylphenyl]pyrrolidine.
Claim 15
Dependent Claim
7 words
The compound according to claim 1, 1-[4-(adamantyloxy)-2-fluorophenyl]pyrrolidine.
Claim 16
Dependent Claim
7 words
The compound according to claim 1, 1-[4-(1-adamantyloxy)-2,6-dimethylphenyl]pyrrolidine.
Claim 17
Dependent Claim
7 words
The compound according to claim 1, 1-[4-(1-diamantyloxy)phenyl]pyrrolidine.
Claim 18
Dependent Claim
8 words
The compound according to claim 1, N-[4-(1-adamantyloxy)phenyl]pyrrolidine hydrochloride.
Claim 19
Dependent Claim
7 words
The compound according to claim 1, [4-(1-adamantyloxy)-3-fluorophenyl]pyrrolidine.
Claim 20
Dependent Claim
45 words
A pharmaceutical dosage unit form adapted to oral administration to obtain hypolipidemic or hypocholesteremic effects consisting essentially of an effective amount for said effects of a compound selected from those of claim 1 in combination with pharmaceutical means which adapt the compound for oral administration.
Claim 21
Dependent Claim
10 words
The composition of claim 19 wherein said compound is N-[p-(1-adamantyloxy)phenyl]pyrrolidine.
Claim 22
Dependent Claim
43 words
A method of obtaining hypolipidemic or hypocholesteremic effects in a mammal which consists essentially of administering orally to said mammal a pharmaceutical dosage unit form supplying an effective amount for hypolipidemic or hypocholesteremic effect of a compound selected from those of claim 1.
Claim 23
Dependent Claim
27 words
The method of claim 21 wherein the amount of compound administered is within the range of from about 0.1 to about 10 grams on a daily basis.
Claim 24
Dependent Claim
10 words
The method of claim 21 wherein said compound is N-[4(1-adamantyloxy)-2-fluorophenyl]pyrrolidine.
References Cited (Backward Citations)
US3423425A
Cited
US3422104A
Cited
US3576000A
Cited
US3472895A
Cited
US3539630A
Cited
US3663617A
Cited
US3663565A
Cited
US3818020A
Cited
US3799759A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-07-18 | 1981-01-17 | 1981-07-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-07-18 | 1985-01-17 | 1985-07-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-07-18 | 1989-01-17 | 1989-07-19 | $7700.00 | Window Closed / Lapsed |